BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ: BCRX · Real-Time Price · USD

8.33

+0.06 (0.73%)

Sep 30, 2026, 4:00 PM EDT - Market closed

BioCryst Pharmaceuticals Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	940.61	874.84	450.71	331.41	270.83	157.17
Revenue Growth	68.72%	94.10%	36.00%	22.37%	72.31%	782.38%
Gross Profit	727.92	691.68	265.01	114.94	10.94	-58.9
Operating Income	429.25	347.3	-1.28	-98.78	-148.44	-177.72
Net Income	-384.67	263.86	-88.88	-226.54	-247.12	-184.06
Earnings Per Share	-1.68	1.21	-0.43	-1.18	-1.33	-1.03
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
United States	548.78	385.96	288.36
Outside United States	53.06	51.7	37.63
Unallocated	273	13.05	5.42
Total	874.84	450.71	331.41

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	352.57	274.75	320.85	388.99	424.31	507.6
Total Debt	836.65	477.33	841.42	848.71	741.45	593.24
Net Cash (Debt)	-484.07	-202.58	-520.57	-459.73	-317.14	-85.64
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-2.11	-0.93	-2.52	-2.39	-1.71	-0.48

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	376.14	347.37	-52.02	-95.14	-161.85	-142.16
Capital Expenditures	-2.76	-2.47	-1.12	-2.17	-1.35	-2.39
Free Cash Flow	373.38	344.9	-53.14	-97.31	-163.2	-144.54
Free Cash Flow Growth	2268.99%	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	77.39%	79.06%	58.80%	34.68%	4.04%	-37.48%
Operating Margin	45.63%	39.70%	-0.28%	-29.81%	-54.81%	-113.07%
Pretax Margin	-40.53%	30.56%	-19.29%	-68.26%	-90.24%	-115.68%
Profit Margin	-40.90%	30.16%	-19.72%	-68.36%	-91.25%	-117.11%
FCF Margin	39.70%	39.42%	-11.79%	-29.36%	-60.26%	-91.97%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '26 Oct 1, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	6.22	-	-	-	-
Forward PE	16.78	33.02	-	-	-	-
P/FCF Ratio	5.70	4.76	-	-	-	-
PS Ratio	2.26	1.88	3.46	3.70	7.90	15.86